Evidence map›Paper›PMID 29562940›Full record

SynthesisWorld journal of surgical oncology2018

Effectiveness of urine fibronectin as a non-invasive diagnostic biomarker in bladder cancer patients: a systematic review and meta-analysis.

Fan Dong, Yifan Shen, Tianyuan Xu, Xianjin Wang, Fengbin Gao, Shan Zhong, Shanwen Chen, Zhoujun Shen

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in World journal of surgical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Ureteral involvement by metastatic malignant disease.Clinical & experimental metastasis · 2019
    Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Fan DongDepartment of Urology, Huashan Hospital, Fudan University, No.12, Middle Urumqi Road, Shanghai, 200040, China.
Yifan ShenDepartment of Urology, Huashan Hospital, Fudan University, No.12, Middle Urumqi Road, Shanghai, 200040, China.
Tianyuan XuDepartment of Urology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Xianjin WangDepartment of Urology, Huashan Hospital, Fudan University, No.12, Middle Urumqi Road, Shanghai, 200040, China.
Fengbin GaoDepartment of Urology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Shan ZhongDepartment of Urology, Huashan Hospital, Fudan University, No.12, Middle Urumqi Road, Shanghai, 200040, China.
Shanwen ChenDepartment of Urology, Huashan Hospital, Fudan University, No.12, Middle Urumqi Road, Shanghai, 200040, China.
Zhoujun ShenDepartment of Urology, Huashan Hospital, Fudan University, No.12, Middle Urumqi Road, Shanghai, 200040, China. shenzj68@sina.cn.ORCID http://orcid.org/0000-0002-1110-7968
Fudan University · CNRuijin Hospital · CN

Funding

National Natural Science Foundation of China No. 81472379Zhejiang Provincial Natural Science Foundation of China No. LY16H160016
6 · The paper itself

Abstract

backgroundPrevious researches pointed out that the measurement of urine fibronectin (Fn) could be a potential diagnostic test for bladder cancer (BCa). We conducted this meta-analysis to fully assess the diagnostic value of urine Fn for BCa detection.

methodsA systematic literature search in PubMed, ISI Web of Science, EMBASE, Cochrane library, and CBM was carried out to identify eligible studies evaluating the urine Fn in diagnosing BCa. Pooled sensitivity, specificity, and diagnostic odds ratio (DOR) with their 95% confidence intervals (CIs) were calculated, and summary receiver operating characteristic (SROC) curves were established. We applied the STATA 13.0, Meta-Disc 1.4, and RevMan 5.3 software to the meta-analysis.

resultsEight separate studies with 744 bladder cancer patients were enrolled in this meta-analysis. The pooled sensitivity, specificity, and DOR were 0.80 (95%CI = 0.77-0.83), 0.79 (95%CI = 0.73-0.84), and 15.18 (95%CI = 10.07-22.87), respectively, and the area under the curve (AUC) of SROC was 0.83 (95%CI = 0.79-0.86). The diagnostic power of a combined method (urine Fn combined with urine cytology) was also evaluated, and its sensitivity and AUC were significantly higher (0.86 (95%CI = 0.82-0.90) and 0.89 (95%CI = 0.86-0.92), respectively). Meta-regression along with subgroup analysis based on various covariates revealed the potential sources of the heterogeneity and the detailed diagnostic value of each subgroup. Sensitivity analysis supported that the result was robust. No threshold effect and publication bias were found in this meta-analysis.

conclusionsUrine Fn may become a promising non-invasive biomarker for bladder cancer with a relatively satisfactory diagnostic power. And the combination of urine Fn with cytology could be an alternative option for detecting BCa in clinical practice. The potential value of urine Fn still needs to be validated in large, multi-center, and prospective studies.

Indexed as

Biomarkers, TumorFibronectinsHumansPrognosisUrinary Bladder NeoplasmsBiomarkers, TumorFibronectinsFN1 protein, humanBiomarkerBladder cancerDiagnosisMeta-analysisUrine fibronectin

Identifiers

PMID29562940
PMCPMC5863379
OpenAlexW2802180192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.